Clinical Trial Update: The INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial (INSTANT) [Phase 4]

View source ↗

Summary

The INSTANT Phase 4 trial evaluating Integrilin (eptifibatide) with stenting in coronary artery disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Integrilin (Eptifibatide)

Snippet

Sponsor: University of Turin, Italy | Conditions: Coronary Artery Disease | Phase 4 | Status: TERMINATED